Vincentage Pharma said its once-daily oral small-molecule GLP-1 receptor agonist, VCT-220, met primary endpoints in a pivotal Phase 3 trial in overweight or obese patients in China. The company plans to submit an NDA for chronic weight management to China’s NMPA. At 52 weeks, VCT-220 delivered mean body weight reductions of about 12.2% (120 mg) and 12.4% (160 mg), compared with roughly 1.3% for placebo. Vincentage framed the results as establishing clinical differentiation for an oral alternative in the GLP-1 market. The Phase 3 readout adds competitive pressure to the category—especially as oral dosing could expand adoption if regulatory review aligns with efficacy and tolerability data.